Literature DB >> 12584724

Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8.

Zhao Zhong Chong1, Shi-Hua Lin, Jing-Qiong Kang, Kenneth Maiese.   

Abstract

Erythropoietin (EPO) modulates primarily the proliferation of immature erythroid precursors, but little is known of the potential protective mechanisms of EPO in the central nervous system. We therefore examined the ability of EPO to modulate a series of death-related cellular pathways during anoxia and free radical induced neuronal degeneration. Neuronal injury was evaluated by trypan blue, DNA fragmentation, membrane phosphatidylserine exposure, protein kinase B phosphorylation, cysteine protease activity, mitochondrial membrane potential, and mitogen-activated protein (MAP) kinase phosphorylation. We demonstrate that constitutive neuronal EPO is insufficient to prevent cellular injury, but that signaling through the EPO receptor remains biologically responsive to exogenous EPO administration. Exogenous EPO is both necessary and sufficient to prevent acute genomic DNA destruction and subsequent phagocytosis through membrane PS exposure, because neuronal protection by EPO is completely abolished by co-treatment with an anti-EPO neutralizing antibody. Through pathways that involve the initial activation of protein kinase B, EPO maintains mitochondrial membrane potential. Subsequently, EPO inhibits caspase 8-, caspase 1-, and caspase 3-like activities linked to cytochrome c release through mechanisms that are independent from the MAP kinase systems of p38 and JNK. Elucidating some of the novel neuroprotective pathways employed by EPO may further the development of new therapeutic strategies for neurodegenerative disorders. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584724     DOI: 10.1002/jnr.10528

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  66 in total

Review 1.  Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury.

Authors:  Z Z Chong; F Li; K Maiese
Journal:  Histol Histopathol       Date:  2005-01       Impact factor: 2.303

Review 2.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

Review 3.  Molecular and cellular immune mediators of neuroprotection.

Authors:  Nicolas P Turrin; Serge Rivest
Journal:  Mol Neurobiol       Date:  2006-12       Impact factor: 5.590

Review 4.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

5.  Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

6.  The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Int J Mol Med       Date:  2007-02       Impact factor: 4.101

Review 7.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

Review 8.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

9.  Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats.

Authors:  Yisheng Zhong; Huiping Yao; Lianfu Deng; Yu Cheng; Xiaoqing Zhou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-09       Impact factor: 3.117

Review 10.  A "FOXO" in sight: targeting Foxo proteins from conception to cancer.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Med Res Rev       Date:  2009-05       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.